Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sublingual morphine: efficacy reviewed

P H Coluzzi1

  • 1St. Joseph Health System Hospice, Orange, California, USA.

Journal of Pain and Symptom Management
|October 14, 1998
PubMed
Summary

Sublingual morphine may not effectively manage breakthrough cancer pain due to inconsistent absorption. Newer formulations are needed for rapid pain relief bypassing the gastrointestinal system.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survey of analgesic use for nonmalignant pain in long-term care facilities in southern California.

Journal of the American Medical Directors Association·2003
Same author

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Pain·2001
Same author

The management of pain in terminally ill cancer patients with difficulty swallowing.

The American journal of hospice & palliative care·2000
Same author

Managing breakthrough pain. New method expands treatment options.

Advance for nurse practitioners·1998
Same author

Cancer pain management: newer perspectives on opioids and episodic pain.

The American journal of hospice & palliative care·1998
Same author

Oral patient-controlled analgesia.

Seminars in oncology·1997

Area of Science:

  • Oncology
  • Pharmacology
  • Pain Management

Background:

  • Current cancer pain guidelines recommend scheduled and as-needed opioid doses.
  • Oral "as needed" opioids present challenges for patients with swallowing difficulties, nausea, or vomiting.
  • Gastrointestinal absorption delays pain relief, which is problematic for rapidly escalating breakthrough pain.

Purpose of the Study:

  • To evaluate the efficacy of sublingual morphine for breakthrough cancer pain.
  • To explore alternative drug administration routes for rapid pain relief in cancer patients.
  • To assess if sublingual morphine provides effective analgesia via a non-gastrointestinal route.

Main Methods:

  • Review of available pharmacological and clinical data on sublingual morphine for cancer pain.
  • Assessment of morphine absorption through the sublingual mucosa.
  • Analysis of clinical trial data for sublingual morphine efficacy and control.

Main Results:

  • Pharmacological data do not consistently support rapid sublingual morphine absorption.
  • Clinical data on sublingual morphine for breakthrough cancer pain are limited, poorly controlled, and inconclusive.
  • Sublingual morphine may not meet the need for rapid, effective analgesia in cancer patients.

Conclusions:

  • Sublingual morphine's efficacy for breakthrough cancer pain is not well-established.
  • There is a need for alternative, rapid-acting formulations for breakthrough cancer pain.
  • Further research into novel analgesic formulations and administration routes is warranted.

Related Experiment Videos